Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. Among authors: nozza s. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A. Tambussi G, et al. Among authors: nozza s. J Infect Dis. 2001 May 15;183(10):1476-84. doi: 10.1086/320188. Epub 2001 Apr 13. J Infect Dis. 2001. PMID: 11319683 Clinical Trial.
Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.
Fortis C, Soldini L, Ghezzi S, Colombo S, Tambussi G, Vicenzi E, Gianotti N, Nozza S, Veglia F, Murone M, Lazzarin A, Poli G. Fortis C, et al. Among authors: nozza s. AIDS Res Hum Retroviruses. 2002 May 1;18(7):491-9. doi: 10.1089/088922202317406637. AIDS Res Hum Retroviruses. 2002. PMID: 12015902 Clinical Trial.
Oral CCR5 inhibitors: will they make it through?
Biswas P, Nozza S, Scarlatti G, Lazzarin A, Tambussi G. Biswas P, et al. Among authors: nozza s. Expert Opin Investig Drugs. 2006 May;15(5):451-64. doi: 10.1517/13543784.15.5.451. Expert Opin Investig Drugs. 2006. PMID: 16634684 Review.
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Canducci F, et al. Among authors: nozza s. Clin Microbiol Infect. 2011 Jun;17(6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x. Epub 2010 Nov 5. Clin Microbiol Infect. 2011. PMID: 20854427 Free article.
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Siccardi M, et al. Among authors: nozza s. Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. Pharmacogenet Genomics. 2010. PMID: 21217360 Clinical Trial.
249 results